Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak
- Authors
- Lee S.H.; Lew W.J.; Kim H.J.; Lee H.-K.; Lee Y.M.; Cho C.H.; Lee E.J.; Lee D.Y.; Ryu S.W.; Oh S.Y.; Kim S.O.; Shim T.S.
- Issue Date
- 2010
- Keywords
- Interferon-gamma release assay; Rifampicin prophylaxis; Serial testing; Tuberculosis
- Citation
- Respiratory Medicine, v.104, no.3, pp 448 - 453
- Pages
- 6
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Respiratory Medicine
- Volume
- 104
- Number
- 3
- Start Page
- 448
- End Page
- 453
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15495
- DOI
- 10.1016/j.rmed.2009.10.006
- ISSN
- 0954-6111
1532-3064
- Abstract
- Even though some studies have reported the results of serial interferon-gamma release assays (IGRAs) during isoniazid prophylactic treatment, serial results have not been reported after rifampicin prophylaxis. A contact investigation was conducted after a tuberculosis (TB) outbreak in an accommodation facility. The tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-GIT) test were performed in 214 contacts with normal chest radiographs. Rifampicin prophylaxis was initiated in TST+/QFT-GIT+ subjects, and the QFT-GIT test was repeated upon completion of 4 months of rifampicin treatment. Among the 214 contacts, the TST and QFT-GIT test results were positive in 67.7% and 56.7%, respectively, and the agreement between the two tests was fair-to-good (78.3%, kappa = 0.55, p < 0.001). The QFT-GIT test was positive in 77% (97/126) of contacts with positive TST results. Rifampicin prophylaxis was completed in 81 subjects with good compliance. Among 74 subjects with valid serial QFT-GIT test results, IFN-γ levels decreased in 97.3% (72/74) of the subjects and QFT-GIT test reversion (positive to negative) was achieved in 31 subjects (41.9%). Subjects without QFT-GIT test reversion had a significantly higher baseline TST induration sizes (18.3 ± 4.8 vs. 14.9 ± 3.4 mm, p < 0.01) and IFN-γ levels (18.6 ± 17.9 vs. 3.2 ± 7.5 IU/mL, p < 0.01) than the subjects with QFT-GIT test reversion. Thus, IGRAs may be useful in evaluating the therapeutic response to rifampicin prophylaxis in TB contacts. However, considering that this was not a controlled study, a prospective controlled study is needed to determine whether rifampicin prophylaxis truly affects QFT-GIT reversion. © 2009 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Pulmonary, Allergy, and Critical Care Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.